Department of Thoracic Surgery Ⅱ, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, PR China.
Oncol Rep. 2013 Jan;29(1):297-305. doi: 10.3892/or.2012.2107. Epub 2012 Oct 26.
The possible involvement of estrogen receptors (ERs) and testicular orphan nuclear receptors (TRs) in human non-small cell lung carcinoma (NSCLC) has been suggested, but their precise roles and their relationship remain largely unknown. This study aimed to investigate whether TR4-associated protein 16 (TRA16) regulates the ERβ and TR2 pathways and could be a potential target in NSCLC. We used tissue microarrays including NSCLC tissues (n=154) and negative controls (n=14) to examine the expression of TRA16 and ERβ, and in vitro reporter gene assays, the mammalian two-hybrid method and immunoprecipitation in Cos-1 cells to investigate the relationships among TRA16, ERβ and TR2. We found that TRA16 was highly expressed in approximately 90% of the NSCLC tissues examined. TRA16 overexpression was significantly associated with TNM stage, tumor size, lymph node metastasis, tumor thrombus in vein, tumor differentiation and prognosis of NSCLC patients, in which TRA16 was shown to be an independent prognostic factor. Introduction of TRA16 into Cos-1 cells enhanced cell proliferation. Co-expression of TRA16 and ERβ in Cos-1 cells using different reporter gene systems and mammalian two-hybrid approaches revealed that TRA16 enhanced ERβ-mediated transcriptional activity. By adopting similar approaches, and immunoprecipitation and immunocytofluorescence assays, we found that TRA16 also interacted with TR2, and blocked the TR2 inhibitory effect on ERβ. Our findings demonstrate that TRA16 could be a promising diagnostic and prognostic biomarker in NSCLC, and promotes cancer cell growth through activation of the ERβ pathway by interacting with ERβ and TR2.
已有研究提示,雌激素受体(ERs)和睾丸孤儿核受体(TRs)可能参与了人类非小细胞肺癌(NSCLC)的发生,但它们的确切作用及其关系在很大程度上仍不清楚。本研究旨在探讨 TR4 相关蛋白 16(TRA16)是否调控 ERβ和 TR2 通路,并可能成为 NSCLC 的潜在治疗靶点。我们使用组织微阵列(包含 NSCLC 组织(n=154)和阴性对照组织(n=14))检测了 TRA16 和 ERβ的表达,通过体外报告基因检测、哺乳动物双杂交方法和 Cos-1 细胞中的免疫沉淀实验研究了 TRA16、ERβ和 TR2 之间的关系。结果发现,在大约 90%的 NSCLC 组织中 TRA16 呈高表达。TRA16 的过表达与 NSCLC 患者的 TNM 分期、肿瘤大小、淋巴结转移、静脉内肿瘤栓子、肿瘤分化和预后显著相关,TRA16 是独立的预后因素。将 TRA16 导入 Cos-1 细胞可增强细胞增殖。在 Cos-1 细胞中,使用不同的报告基因系统和哺乳动物双杂交方法共表达 TRA16 和 ERβ,结果显示 TRA16 增强了 ERβ 介导的转录活性。采用类似方法,通过免疫沉淀和免疫细胞荧光实验,我们发现 TRA16 还与 TR2 相互作用,并阻断了 TR2 对 ERβ的抑制作用。综上,我们的研究结果表明,TRA16 可能是 NSCLC 有前途的诊断和预后生物标志物,通过与 ERβ和 TR2 相互作用激活 ERβ 通路,促进癌细胞生长。